BTB Therapeutics
June 24, 2026
Theater 2
Type: Company Presentation
Focus Area:
Pain Management
BTB Therapeutics is a clinical stage drug development company with BTB-101 (a non-opioid analgesic) for acute post-op pain management in Phase 2, and small molecule-based RNA splicing modifiers for rare diseases and immuno-oncology indications.
https://www.btbtherapeutics.com/en/
Company HQ City:
ESCONDIDO
Company HQ State:
CA
Company HQ Country:
United States
Year Founded:
2020
Lead Product in Development:
BTB-101, a non-opioid analgesic, for acute post-op pain managment
CEO
Takashi Kiyoizumi, MD, PhD (CEO)
Development Phase of Lead Product
Phase II
Number of Unlicensed Products Looking for Licensing
3
When you expect your next catalyst update?
July, 2026
What is your next catalyst (value inflection) update?
US IND submission and initiateion of Phase 1b+Phase 2a
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}